에 대한 최신 뉴스 Humana (NYSE:HUM) 주식

Humana

Humana is one of the largest private health insurers in the US with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Health Care

Technicals

Trading Ideas

최고의 트레이더는 공격을 하지 않는다. 그들은 수비를 한다. 그들은 트레이드할 때 반응적이다. 그들은 시장이 그들에게 무엇을 해야 할지 말하도록 놔둔다.

오늘의 주식: 휴마나가 이전의 지지선을 기억하고 있을까?

Large Cap

News

Movers

ADBE

ALLY

BEKE

MRNA

RYAAY

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 렌토킬 이니셜(NYSE:RTO)의 주가가 19.65% 급락했다. 이는 회사가 2024 회계연도 하반기 가이던스를 수정한 후 발생한 일이다.

모더나, 타이슨 푸드 및 어도비는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 8일-9월 14일)

Government

Regulations

After-Hours Center

Insurance

월요일 애프터마켓에서는 UnitedHealth Group Inc(NYSE:UNH), Humana Inc(NYSE:HUM)와 CVS Health Corp(NYSE:CVS)를 포함한 여러 의료 보험 회사들의 주가가 떨어진 채로 거래가 이루어졌습니다. 이는 메디케어 및 메디테이드서비스센터(CMS)가 2025년 메디케어 어드밴티지 및 메디케어 파트 D 계획에 대한 결제 업데이트를 확정한 후 발생한

월요일 장 마감 후 유나이티드헬스, 휴매나, CVS 주식 하락; 왜?

Humana Inc

Humanscape

Humacyte Inc

Humble & Fume Inc

Anthropos Capital Corporation

Hua Medicine

Humm Group Ltd

Humble Energy Inc

HUMMINGBIRD RES LTD ORD by Hummingbird Resources Ltd

Hummingbird Resources PLC

Humatech Inc

UBS analyst Kevin Caliendo maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and lowers the price target from $380 to $250.

Price Target

Analyst Ratings

UBS Maintains Neutral on Humana, Lowers Price Target to $250

Piper Sandler analyst Jessica Tassan downgrades Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) from Overweight to Neutral and lowers the price target from $392 to $274.

Downgrades

Piper Sandler Downgrades Humana to Neutral, Lowers Price Target to $274

Deutsche Bank analyst George Hill maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and lowers the price target from $349 to $250.

Deutsche Bank Maintains Hold on Humana, Lowers Price Target to $250

Oppenheimer analyst Michael Wiederhorn maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Outperform and lowers the price target from $400 to $280.

Oppenheimer Maintains Outperform on Humana, Lowers Price Target to $280

B of A Securities analyst Kevin Fischbeck downgrades Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) from Neutral to Underperform and lowers the price target from $376 to $247.

B of A Securities Downgrades Humana to Underperform, Lowers Price Target to $247

The best traders don't play offense. They play defense. When they trade, they are reactionary. They let the market tell them what to do.
These traders know that the market has a &#8220;memory.&#8221; This means that important support and resistance levels can stay intact for long periods of time. It could be weeks, months — or even years. 
As you can see on the chart, this could be the case with the $225 level for Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>). This is why our team of technical analysis experts has made it our Stock of the Day.
If a stock is trending lower, there isn't enough demand to absorb all of the supply. Sellers are forced to offer their shares out at a discount if they want to find someone to buy them. This action forces the shares into a downtrend.
Downtrends end when they reach support. At support levels, there is enough demand (buy orders) to absorb all of the supply (sell orders).
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="627" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3-1024x627.png" alt="" class="wp-image-577237" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3-1024x627.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3-768x470.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3.png 1182w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/news/24/10/41143156/oil-prices-spike-energy-stocks-jump-after-irans-missile-attack-on-israel-what-investors-need-to-know">Oil Prices Spike, Energy Stocks Jump After Iran&#8217;s Missile Attack On Israel: What Investors Need To Know</a>
The $225 level first became support for Humana in April 2019. Then it was support again in March 2020. This was a case of &#8220;market memory.&#8221;
Support can stay intact for extended periods of time because of remorseful or regretful sellers. These are people who sold their shares while they were at support, but regretted doing so after the stock rallied and the price moved higher.
Some of these disappointed sellers vow to buy their shares back. But they will only do so if they can get them at the same price they were sold.
As a result, when the shares eventually return to the support level, they enter buy orders. If there are a large number of these buy orders, it will create support at the level that had been support before.
<a href="https://www.benzinga.com/government/24/10/41140319/humana-faces-sharp-decline-in-medicare-star-ratings-for-2025-braces-for-2026-revenue-hit">After some disappointing news</a>, Humana is selling off and once again getting close to the important $225 level. If it does get there, there is a good chance that the market &#8220;remembers&#8221; this level was support before.
This means there is a good chance that it finds a bottom. It also means there is a good chance the stock reverses and rallies off of this level just like it did in April 2019 and March 2020.
Read Next: • <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41147552/bitcoin-drops-below-62-000-as-analysts-warn-of-potential-further-decline">Bitcoin Drops Below $62,000 As Analysts Warn Of Potential Further Decline</a>

Photo: T. Schneider via Shutterstock

Stock Of The Day: Will Humana Remember?

U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 0.2% on Wednesday.
The Dow traded up 0.07% to 42,186.44 while the NASDAQ gained 0.24% to 17,952.61. The S&amp;P 500 also rose, gaining, 0.03% to 5,710.22.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/41091653/how-to-earn-500-a-month-from-mccormick-stock-ahead-of-q3-earnings">How To Earn $500 A Month From McCormick Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Information technology shares jumped by 0.6% on Wednesday.
In trading on Wednesday, consumer staples shares dipped by 1%.
Top Headline
ConAgra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) reported weaker-than-expected first-quarter results.
ConAgra reported quarterly adjusted earnings per share of 53 cents, missing the analyst consensus of 60 cents. Net sales of $2.79 billion (down 3.8%) missed the street view of $2.84 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares shot up 25% to $6.02 after the company announced that Toyota will invest an additional $500 million to support the certification and commercial production of the electric air taxi.</li>
<li>Shares of RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) got a boost, surging 7% to $128.37 after the company reported better-than-expected first-quarter adjusted EPS results.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares were also up, gaining 46% to $0.6818. Shares of US-listed Chinese stocks traded higher on continued strength following recent stimulus measures and the start of the National Day Golden Week.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares dropped 13% to $242.64 after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.</li>
<li>Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) were down 34% to $2.35 after the company announced it will be delisted from the Nasdaq.</li>
<li>Aditxt Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) was down, falling 30% to $3.1318. Aditxt recently announced a 1-for-40 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 0.4% to $70.08 while gold traded down 0.7% at $2,672.80.
Silver traded up 0.8% to $31.980 on Wednesday, while copper rose 1.3% to $4.65.
Euro zone
European shares closed mixed today. The eurozone's STOXX 600 rose 0.05%, Germany's DAX fell 0.25% and France's CAC 40 rose 0.05%. Spain's IBEX 35 Index fell 0.55%, while London's FTSE 100 gained 0.17%.
The unemployment rate in the Eurozone came in unchanged from the previous month at 6.4% in August.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 dipping 2.18% and Hong Kong's Hang Seng Index jumping 6.20%.
Economics
<ul>
<li>Private businesses in the U.S. added 143,000 workers to their payrolls during the month of September compared to a revised 103,000 gain in August and higher than market estimates of 124,000, the ADP said.</li>
<li>The EIA said crude oil inventories in the U.S. climbed by 3.889 million barrels for the week ended Sept. 27, versus market estimates of a 1.3 million decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41141190/nike-to-100-here-are-10-top-analyst-forecasts-for-wednesday">Nike To $100? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Markets

ADTX

EGRX

JOBY

Crude Oil Edges Higher; ConAgra Posts Downbeat Earnings

Stephens &amp; Co. analyst Scott Fidel downgrades Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) from Overweight to Equal-Weight and lowers the price target from $400 to $250.

Stephens & Co. Downgrades Humana to Equal-Weight, Lowers Price Target to $250

Live On CNBC, Steve Weiss Announces Bought Humana

Leerink Partners analyst Whit Mayo downgrades Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) from Outperform to Market Perform and lowers the price target from $400 to $250.

Leerink Partners Downgrades Humana to Market Perform, Lowers Price Target to $250

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 100 points on Wednesday.
The Dow traded up 0.24% to 42,256.16 while the NASDAQ rose 0.27% to 17,958.08. The S&amp;P 500 also rose, gaining, 0.16% to 5,717.63.
Leading and Lagging Sectors Information technology shares jumped by 0.9% on Wednesday.
In trading on Wednesday, real estate shares dipped by 0.9%.
Top Headline
NIKE, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) reported mixed first-quarter results on Tuesday.
The company reported first-quarter revenue of $11.59 billion, missing analyst estimates of $11.65 billion. The athletic footwear and apparel company reported first-quarter earnings of 70 cents per share, beating analyst estimates of 52 cents per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares shot up 20% to $5.74 after the company announced that Toyota will invest an additional $500 million to support the certification and commercial production of the electric air taxi.</li>
<li>Shares of Great Lakes Dredge &amp; Dock Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) got a boost, surging 10% to $11.77 after the company announced the receipt of several dredging awards totaling $342.3 million.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares were also up, gaining 38% to $0.6480. Shares of US-listed Chinese stocks traded higher on continued strength following recent stimulus measures and the start of the National Day Golden Week.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares dropped 18% to $230.39 after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.</li>
<li>Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) were down 36% to $2.28 after the company announced it will be delisted from the Nasdaq.</li>
<li>Aditxt Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) was down, falling 31% to $3.05. Aditxt recently announced a 1-for-40 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $70.22 while gold traded down 0.8% at $2,669.60.
Silver traded up 1% to $32.03 on Wednesday, while copper rose 1% to $4.6350.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.01%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.09%. Spain's IBEX 35 Index fell 0.65%, while London's FTSE 100 gained 0.14%.
The unemployment rate in the Eurozone came in unchanged from the previous month at 6.4% in August.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 dipping 2.18% and Hong Kong's Hang Seng Index jumping 6.20%.
Economics
<ul>
<li>Private businesses in the U.S. added 143,000 workers to their payrolls during the month of September compared to a revised 103,000 gain in August and higher than market estimates of 124,000, the ADP said.</li>
<li>The EIA said crude oil inventories in the U.S. climbed by 3.889 million barrels for the week ended Sept. 27, versus market estimates of a 1.3 million decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41141190/nike-to-100-here-are-10-top-analyst-forecasts-for-wednesday">Nike To $100? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Intraday Update

GLDD

Dow Gains 100 Points; Joby Aviation Shares Spike Higher

Whales with a lot of money to spend have taken a noticeably bearish stance on Humana.
Looking at options history for Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) we detected 47 trades.
If we consider the specifics of each trade, it is accurate to state that 29% of the investors opened trades with bullish expectations and 55% with bearish.
From the overall spotted trades, 33 are puts, for a total amount of $3,936,662 and 14, calls, for a total amount of $568,563.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $160.0 to $400.0 for Humana over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Humana stands at 304.11, with a total volume reaching 9,185.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Humana, situated within the strike price corridor from $160.0 to $400.0, throughout the last 30 days.
<h3>Humana 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727879545_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$25.0</td>
<td>$23.0</td>
<td>$24.2</td>
<td>$255.00</td>
<td>$847.0K</td>
<td>785</td>
<td style="text-align: right;">757</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$26.3</td>
<td>$24.5</td>
<td>$24.5</td>
<td>$255.00</td>
<td>$612.5K</td>
<td>785</td>
<td style="text-align: right;">257</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$23.0</td>
<td>$19.1</td>
<td>$23.0</td>
<td>$230.00</td>
<td>$575.0K</td>
<td>1.1K</td>
<td style="text-align: right;">95</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$10.3</td>
<td>$9.6</td>
<td>$10.3</td>
<td>$210.00</td>
<td>$257.5K</td>
<td>46</td>
<td style="text-align: right;">290</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$12.2</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$205.00</td>
<td>$228.0K</td>
<td>0</td>
<td style="text-align: right;">222</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Where Is Humana Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 7,640,114, the HUM's price is down by -17.04%, now at $231.83. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 28 days.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $396.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $395. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Humana with a target price of $400. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $395. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $395.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Humana, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Humana Options Trading: A Deep Dive into Market Sentiment

According to preliminary data from the Centers for Medicare and Medicaid Services (CMS), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) faces a substantial drop in its Medicare Advantage (MA) <a target="_blank" href="https://www.benzinga.com/quote/hum" rel="noreferrer noopener">Star Ratings for 2025</a>.
The data available in the CMS Plan Finder as of October 1, 2024, reveals that only 25% of Humana&#8217;s members are enrolled in plans rated four stars and above, a sharp decline from 94% in 2024.
The decrease is primarily driven by contract H5216, which holds around 45% of Humana&#8217;s MA membership and 90% of its employer group waiver plan (Group MA) membership.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth</a>.
H5216&#8217;s <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000049071/000004907124000045/hum-20241002.htm" rel="noreferrer noopener">rating</a> dropped to 3.5 stars from 4.5 stars, affecting the company&#8217;s quality bonus payments in 2026. CMS is expected to release the official 2025 Star Ratings around October 10.
Humana attributes the lower star ratings to narrowly missing higher industry benchmarks based on a few key measures.
The company has raised concerns regarding potential errors in CMS&#8217;s calculation of certain results and industry thresholds. While appeals are still pending, Humana has requested further clarification from CMS to ensure the accuracy of its ratings.
The company plans to engage closely with CMS to address these issues and ensure that the Star Ratings accurately reflect the quality of its plans.
Despite its efforts to appeal the results, Humana expressed disappointment with its 2025 performance. It has launched initiatives to improve operational discipline and reclaim its leadership position in MA Star Ratings.
Humana expects the changes to drive improvements in key performance areas and positively impact quality bonus payments by 2027.
Looking ahead, Humana is exploring options to mitigate the potential revenue loss anticipated in 2026 due to the drop in Star Ratings.
It does not expect these ratings to affect its financial outlook for 2024 or 2025. Humana reaffirmed 2024 adjusted EPS of ~$16.00 versus the consensus of $20.31. Humana expects a 2024 insurance segment benefit <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/40070046/insurance-giant-humana-stock-tumbles-after-q2-earnings-beat-issues-sub-par-profit-outlook" rel="noreferrer noopener">ratio of approximately 90%</a>.
However, while Humana remains focused on achieving its goal of a 3% margin in individual MA by 2027, the likelihood of meeting this target has become more uncertain due to the 2025 ratings outcome.
Price Action: HUM stock is down 20.10% at $223.23 during the premarket session at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation" target="_blank" rel="noreferrer noopener">Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation</a>.</li>
</ul>
Photo: T. Schneider via Shutterstock

General

Humana Faces Sharp Decline In Medicare Star Ratings For 2025, Braces For 2026 Revenue Hit

HUM: -25% &#x7C; <a href="https://www.benzinga.com//node/41137484">Humana shares are trading lower after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.</a>
&nbsp;
NKE: -8% &#x7C; <a href="https://www.benzinga.com//node/41138743">Nike shares are trading lower after the company missed Q1 revenue estimates.</a>
&nbsp;
TGL: 74% &#x7C; <a href="https://www.benzinga.com//node/41138720">Treasure Global shares are trading higher after the company announced that it has completed its previously disclosed at-the-market equity offering program.</a>

Market-Moving News for October 2nd

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Wednesday.
Shares of NIKE, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) fell sharply in today's pre-market trading f<a href="https://www.benzinga.com/news/earnings/24/10/41129610/nike-q1-earnings-revenue-miss-eps-beat-teams-energized-amid-ceo-transition-a-comeback-at-this-scale">ollowing first-quarter results</a>.
The company reported first-quarter revenue of $11.59 billion, missing analyst estimates of $11.65 billion. The athletic footwear and apparel company reported first-quarter earnings of 70 cents per share, beating analyst estimates of 52 cents per share.
NIKE shares declined 5.5% to $84.25 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares declined 24% to $212.77 in pre-market trading after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.</li>
<li>TC Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRP#NYSE">TRP</a>) dipped 7.1% to $44.94 in pre-market trading. TC Energy provided conversion right and dividend rate notice for Series 9 and 10 preferred shares.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) shares fell 6.9% to $9.31 in pre-market trading after dipping over 15% on Tuesday.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) shares declined 6% to $18.00 in pre-market trading.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) shares fell 4.5% to $62.00 in pre-market trading. The company reported better-than-expected earnings for its third quarter and announced plans to cut approximately 4% of the global workforce and eliminate unfilled job positions.</li>
<li>Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares declined 4.4% to $0.7290 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares fell 3.4% to $14.50 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy">Jim Cramer Hand Picks These 3 Stocks To Ride The Crest Of The Chinese Stimulus Frenzy</a></li>
</ul>

Pre-Market Outlook

ALHC

BLCO

CAPR

LILM

Nike Reports Weak Sales, Joins Lamb Weston And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock moved upwards by 19.9% to $1.17 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) shares rose 17.4% to $17.0. The company's market cap stands at $242.0 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock increased by 11.81% to $0.23. The market value of their outstanding shares is at $5.5 million. </li>
<li>Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) stock moved upwards by 9.72% to $3.95. The company's market cap stands at $1.0 billion. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock rose 9.3% to $0.33. The company's market cap stands at $23.6 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock rose 8.49% to $1.15. The market value of their outstanding shares is at $29.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares declined by 21.8% to $218.63 during Wednesday's pre-market session. The company's market cap stands at $26.3 billion. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock fell 12.63% to $0.38. The market value of their outstanding shares is at $7.9 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock decreased by 11.87% to $0.22. The market value of their outstanding shares is at $1.3 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock declined by 11.03% to $1.21. The company's market cap stands at $15.5 million. </li>
<li>IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) shares declined by 9.18% to $13.17. The market value of their outstanding shares is at $781.2 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 8.22% to $0.51. The market value of their outstanding shares is at $4.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUTL

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CTCX

ERNA

IGMS

KAPA

MHUA

MODV

SLXN

TIVC

XAIR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

Humana shares are trading lower after the company provided update on decline in Stars performance for 2025 and how it will impact quality bonus payments in 2026.

Despite on-going appeal efforts, the Company is disappointed with its performance and has initiatives underway focused on improving its operating discipline and returning to an industry leading Stars position as quickly as possible. These initiatives are expected to impact performance across key measures and drive improved quality bonus payments in 2027 and beyond.
In addition, the Company remains focused on achieving its individual MA margin target of &lsquo;at least 3 percent&rsquo;, although there is now more risk in its ability to fully achieve this result by 2027.

Humana Expects 2025 Stars Results Not To Impact Financial Results Or Outlook For 2024 Or 2025

Based on preliminary 2025 Medicare Advantage (MA) Star Ratings data provided by the Centers for Medicare and Medicaid Services (CMS), which became available in CMS Plan Finder as of October 1, 2024, Humana Ihas approximately 1.6 million, or 25%, of its members currently enrolled in plans rated 4 stars and above for 2025, a reduction from 94% in 2024.
A significant driver of these results was contract H5216 decreasing to a 3.5-star rating from a 4.5-star rating in 2024.&nbsp;The decline in Stars performance for 2025 will impact Humana&rsquo;s quality bonus payments in 2026. 2025 Star rating details are expected to be formally released by CMS on or around October 10th.

Guidance

Humana Says Exploring All Available Options To Mitigate Expected 2026 Revenue Headwind Related To Its 2025 Star Ratings In The Event Its Challenges To Results Are Unsuccessful - FIling

Throughout the last three months, 12 analysts have evaluated Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $388.0, a high estimate of $407.00, and a low estimate of $349.00. Surpassing the previous average price target of $374.08, the current average has increased by 3.72%.
<img src="https://www.benzinga.com/files/images/story/2024/1727798465_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Humana among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$396.00</td>
<td>$332.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$349.00</td>
<td>$341.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$364.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$407.00</td>
<td>$396.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$400.00</td>
<td>$355.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Humana's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>Discovering Humana: A Closer Look</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Financial Insights: Humana</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Humana's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 10.44%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 2.3%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.14%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Humana's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.36%, the company showcases efficient use of assets and strong financial health.
Debt Management: Humana's debt-to-equity ratio surpasses industry norms, standing at 0.77. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Have This To Say About Humana

Analyst Erin Wright of Morgan Stanley maintained a Hold rating on Humana (HUM – Research Report), with a price target of $374.00. Erin Wright's rat...

Humana's Star Rating Decline Prompts Hold Rating Amid Financial Uncertainty

Humana cut to underperform by BofA on margin recovery delay

Humana (HUM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Baxter from Wells Fargo ...

Buy Rating Affirmed: Humana's Proactive Strategies to Mitigate Earnings Headwinds

In a report released today, Jailendra Singh from Truist Financial assigned a Hold rating to Humana (HUM – Research Report). The company's shares cl...

Truist Financial Releases a Hold Rating on Humana (HUM)

Deutsche Bank analyst George Hill maintained a Hold rating on Humana (HUM – Research Report) today and set a price target of $250.00. The company's...

Humana (HUM) Receives a Hold from Deutsche Bank

Humana extends slide as Piper Sandler downgrades on Star Ratings update

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) investors are facing tough times. This week, the company's stock took a hit after news broke that the health insurance and health...

'Time to Jump Ship,' Says Bank of America About Humana Stock

Vltava Fund Q3 2024 Letter To Shareholders

UnitedHealthcare is latest to sue Medicare over Star Ratings

AAPL

KLAC

Press Releases

Humana and Interwell Health Announce Addition of State of Florida to Value-based Kidney Care Program

New Health Webinars From CenterWell and Conviva Empower Seniors to Take Active Role in Their Health

Humana Inc. to Release Third Quarter 2024 Results on October 30, 2024

Humana's 2025 Medicare Advantage Plans Focus on Quality, Affordable Healthcare Tailored to the Needs of Consumers

Humana Foundation Donates $1 Million to Support Disaster Recovery in the Wake of Hurricane Helene

HUM Investors Have Opportunity to Join Humana Inc. Fraud Investigation with the Schall Law Firm

The Law Offices of Frank R. Cruz Announces Investigation of Humana Inc. (HUM) on Behalf of Investors

Legal

Johnson Fistel Begins Investigation into Humana, Inc. Following a Significant Drop in the Company's Stock

NYSE: HUM Lawsuit against Directors filed - Investors in shares of Humana Inc. (NYSE: HUM) should contact the Shareholders Foundation

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humana Inc. (HUM) on Behalf of Investors

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

HealthEquity

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Piper Sandler

Deutsche Bank

Oppenheimer

B of A Securities

최고의 트레이더는 공격을 하지 않는다. 그들은 수비를 한다. 그들은 트레이드할 때 반응적이다. 그들은 시장이 그들에게 무엇을 해야 할지 말하도록 놔둔다.
이러한 트레이더들은 시장이 &#8220;기억&#8221;을 가지고 있다는 것을 알고 있다. 이는 중요한 지지선과 저항선이 오랜 기간 동안 유지될 수 있음을 의미한다. 몇 주, 몇 달, 심지어 몇 년이 걸릴 수도 있다.
이 차트에서 보듯이, 이는 휴마나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)의 $225 수준이 그럴 수 있다. 그래서 이를 저희 기술 분석 전문가들 팀이 오늘의 주식으로 선정했다.
주식이 하락세를 보일 때는 수요가 공급을 모두 흡수할 만큼 충분하지 않다는 것이다. 매도자들은 누군가가 주식을 사도록 유도하기 위해 할인된 가격으로 주식을 내놓아야 한다. 이 행동은 주식을 하락세로 몰아넣는다.
하락세는 지지선에 도달했을 때 끝난다. 지지선에서는 수요(매수 주문)가 공급(매도 주문)을 모두 흡수할 만큼 충분하기 때문에 하락세가 멈춘다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02144136/1-3-1024x627.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
휴마나의 차트에서 $225 수준은 2019년 4월에 처음 지지선이 된 후 2020년 3월에도 다시 지지선이 되었다. 이것이 바로 &#8220;시장 기억&#8221;의 사례이다.
지지선은 판매자들이 후회할 경우 오랜 기간 동안 유지될 수 있다. 이들은 지지선에서 주식을 팔았다가 주가가 오르고 가격이 더 오른 후에 그렇게 한 것을 후회한 사람들이다.
실망한 판매자들 중 일부는 자신의 주식을 다시 사겠다고 다짐한다. 그러나 그들은 판매된 가격과 동일한 가격으로 구입할 수 있는 경우에만 그렇게 할 것이다.
결과적으로 주가가 다시 지지선에 도달하면, 이들은 매수 주문을 넣는다. 이러한 매수 주문이 많으면 이전에 지지선이 되었던 가격에서 다시 지지선을 형성하게 된다.
<a href="https://www.benzinga.com/government/24/10/41140319/humana-faces-sharp-decline-in-medicare-star-ratings-for-2025-braces-for-2026-revenue-hit" target="_blank" rel="noopener" data-google-interstitial="false">최근에 몇 가지 실망스러운 뉴스가 있은 후</a>, 휴마나에 매도세가 발생하고 다시 중요한 $225 수준에 가까워지고 있다. 이 가격에 도달하면 시장이 이전에 이 수준이 지지선이었음을 &#8220;기억&#8221;할 가능성이 높다.
이는 주가가 바닥을 찾을 가능성이 높다는 것을 의미한다. 또한, 주가가 이 수준에서 반전되어 상승할 가능성이 높다는 것을 의미한다. 이는 2019년 4월과 2020년 3월과 같은 경우이다.
주가 움직임: 휴마나의 주식은 수요일 11.79% 하락한 $246.49에 마감되었다.
다음 읽기: 
• <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41147552/bitcoin-drops-below-62-000-as-analysts-warn-of-potential-further-decline" target="_blank" rel="noopener" data-google-interstitial="false">분석가들이 추가 하락 가능성을 경고하면서 비트코인이 62,000달러 아래로 하락</a>
Photo: T. Schneider via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 렌토킬 이니셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>)의 주가가 19.65% 급락했다. 이는 회사가 <a href="https://www.benzinga.com//node/40814655" target="_blank" rel="noreferrer noopener">2024 회계연도 하반기 가이던스</a>를 수정한 후 발생한 일이다.
2. 앨라이 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>)의 주가가 17.31% 급락했다. 이 회사의 CFO가 <a href="https://www.benzinga.com//node/40800069" target="_blank" rel="noreferrer noopener">컨퍼런스에서 차입자들 간의 신용 문제</a>가 심화되고 있음을 언급한 후 여러 애널리스트들이 <a href="https://www.benzinga.com//node/40811970" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>했다.
3. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주가가 11.26% 하락했다. 이 회사가 2027년까지 R&amp;D 비용을 11억 달러 줄이고 <a href="https://www.benzinga.com//node/40834547" target="_blank" rel="noreferrer noopener">2025년 매출 전망을 예상보다 낮게</a> 발표한 후, 많은 애널리스트들이 <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>했다.
4. 휴매나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)의 주가가 9.93% 하락했다. 이는 이번 주의 <a href="https://www.benzinga.com/general/entertainment/24/09/40840076/trump-vs-harris-presidential-debate-viewership-tops-trump-biden-total-but-falls-short-of-re" target="_blank" rel="noreferrer noopener">트럼프-해리스 토론</a>과 관련이 있을 수 있다.
5. 타이슨 푸드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>)의 주가가 7.57% 하락했다.
6. KE 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>)의 주가가 7.14% 하락했다.
7. 어도비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)의 주가가 5.69% 하락했다. 이는 3분기 실적 발표 후 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/ADBE/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측을 하향 조정</a>한 결과이다.
8. 라이언에어 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYAAY#NASDAQ">RYAAY</a>)의 주가가 5.38% 하락했다.
9. JP모건 체이스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)의 주가가 5.05% 하락했다. 이는 COO가 애널리스트의 전망을 완화한 후 발생한 일이다.
10. 데번 에너지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)의 주가가 4.87% 하락했다. JP 모건 애널리스트가 데번 에너지를 비중 확대 등급으로 유지하고 <a href="https://www.benzinga.com/quote/ADBE/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 64달러에서 51달러로 하향 조정</a>했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%B8%84%EC%9D%B4-%EB%B8%8C%EB%A1%9C%EB%93%9C%EC%BB%B4-%EB%B0%8F-arm%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10%EA%B0%9C/" target="_blank" rel="noopener">츄이, 브로드컴 및 ARM은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (9월 8일-9월 14일)</a></li>
</ul>
사진 출처: Lutsenko_Oleksandr on Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

월요일 시간외 거래에서 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), 휴매나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)와 CVS 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)를 포함한 여러 의료 보험 회사들의 주가가 하락했다. 이는 메디케어 및 메디테이드서비스 센터(CMS)가 <a href="https://www.cms.gov/newsroom/press-releases/cms-finalizes-payment-updates-2025-medicare-advantage-and-medicare-part-d-programs">결제 업데이트를 확정</a>한 후 발생한 일이다.
사건의 전말: CMS는 월요일, 메디케어 어드밴티지(MA) 및 메디케어 파트 D 처방약(파트 D) 프로그램에 대한 2025년도 요율 발표를 확정하고 이 프로그램에 대한 결제 정책을 업데이트하고 결제 정확도를 보장하도록 했다고 발표했다.
이번 요율 발표에 따르면, 2024년부터 2025년까지 평균적으로 정부로부터 MA 계획에 대한 지급이 3.7% 증가할 것으로 예상된다. 또한 2025 년 미 연방정부는 사설 보험 계획에 대해 500 ~ 600 억 달러 사이의 MA 지급을 예상하고 있다.
CMS는 또한 2025년 메디케어 파트 D 약물 혜택 구조를 개선하여 약값을 낮출 예정이라고 밝혔다. 2025년에 메디케어 파트 D를 가입한 사람들의 연간 최대 부담 비용은 2,000 달러로 제한될 것이다.
&#8220;대통령의 하위 처방약에 대한 비용을 낮추게 해주는 인플레이션 감축법(IRA) 덕분에 다음 해에 메디케어 파트 D를 가입한 수백만 명의 사람들은 약값이 더욱 낮아질 것이다. 여러분의 처방약에 대한 금액 지불은 2,000달러를 초과하지 않도록 제한될 것이다. 이로써 여러분은 더 많은 돈을 주머니에 넣을 수 있다&#8221; 라며 미국 보건인구사회부의 자비에르 베서라(Xavier Becerra) 행정부 장관은 말했다.
&#8220;파트 D 약물 혜택 개선은 물론, 이번 결제 업데이트로 인해 이들 프로그램에 의존하는 메디케어 관리 보험 계획에 대한 결제도 개선되었다. 바이든-해리스 행정부는 미국 국민들의 건강 관리 비용을 계속해서 낮추겠다. 이는 대통령이 한 약속을 지키기 위한 것이다.&#8221;
다른 뉴스들: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38030693/galapagos-downgraded-pharma-firm-faces-uphill-battle-with-slow-pipeline-progress">Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst</a>
UNH, HUM, CVS 주가 움직임: 월요일 시간외 거래에서, <a href="http://pro.benzinga.com">Benzinga Pro</a>(벤징가 프로) 따르면, 미국 헬스케어의 주가는 해당 뉴스로 4.5% 하락했다. 휴매나는 9.6% 하락했으며, CVS 주식은 5.92% 빠졌다.
사진: UnitedHealth의 제공

2024년 1분기는 대부분의 자산 클래스에게는 <a href="https://www.benzinga.com/etfs/sector-etfs/24/03/37994542/gold-prices-rise-to-all-time-highs-mark-best-month-in-4-years-mining-stocks-rally-as-traders-ant" target="_blank" rel="noreferrer noopener">대성공이었다</a>. 이러한 강세는 상슨의 지속가능성에 대한 투자자들의 우려를 불러일으켰다. 
이 자산 클래스들의 파티는 언제까지 이어질 것인가? 오버보팅된 시장에 투자하는 데 포함되는 위험은 무엇인가? Benzinga는 이번 랠리가 어떻게 이루어졌는지, 그리고 근거 리스크와 비슷한 기회에 집중해 애널리스트와 경제학자들의 견해를 정리했다.
주식 시장 &#8211; 부진에서 강세로: 주식시장은 새해에 회복세로 출발했는데, 2023년의 급등세가 이어질 것이란 우려가 있었다. 그러나 작년의 힘이 이어졌으며, 이를 통해 회의론이 무너지고 주식시장이 새로운 최고점을 찍었다. 
1분기 동안 S&amp;P 500 지수는 종가 및 일중거래 기록 최고점을 기록했다. 블루칩 주식들도 이러한 성과를 반영하며 다우존스산업평균지수(Dow Jones Industrial Average)는 1분기를 새로운 기록으로 마감했다. 
기술주는 다시 한번 AI 붐을 이끌었으며, 이로 인해 다양한 크기의 회사들은 이익을 창출했다. 그러나 기술주 중심의 나스닥종합지수는 기간 내 상승세 중 일부 이유로 쿼터 말부근 몇몇 이익 실현을 위한 이유로 레코드 피크에 도달하지 못했다. 
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="650" height="450" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/28222154/newplot-7.jpeg" alt="" class="wp-image-269973" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/28222154/newplot-7.jpeg 650w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/28222154/newplot-7-300x208.jpeg 300w" sizes="(max-width: 650px) 100vw, 650px" /></figure>
 출처: Benzinga 
이번 랠리의 더욱 마음이 편한 측면은 2023년과는 다르게 기술주가 아닌 다른 부문에서 더 많은 참여가 이루어졌다는 점이다. 
LPL Financial의 주요 기술 전문가인 아담 턴퀴스트(Adam Turnquist)는 최근 노트에서 S&amp;P 500 지수의 강세 추세가 참여와 순환적 리더십에 의해 지지받고 있다고 말했다. &#8220;종업원들, 금융기업 및 자원은 주로 메가캡스와 AI 열광으로 인해 거의 주목받지 못했던 매력적인 회전을 입증하는 증거를 제시했다&#8221;고 그는 말했다. 
참고 자료:<a target="_blank" href="https://www.benzinga.com/money/how-to-start-investing-in-stocks" rel="noreferrer noopener">주식 초보자 투자 가이드</a>
기간 초반에 AI의 낙관적인 전망은 실리콘엔엔딩 일부 주식의 상승을 견인했는데, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 및 Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)와 같은 기업이 올해 강세를 표명했다. 후반에는 이러한 주식들이 연방준비제도(Fed)의 금리 인하에 대한 경향을 반영하면서 다음과 같은 지지를 받았다.
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td></td>
<td>현재 수준</td>
<td>분기 내 변동</td>
<td>2023년 성과</td>
</tr>
<tr>
<td>나스닥종합지수</td>
<td>16,379.46</td>
<td>+9.11%</td>
<td>+43.42%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,254.35&#x2A;</td>
<td>+10.16%</td>
<td>+24.23%</td>
</tr>
<tr>
<td>다우존스산업평균지수</td>
<td>39,807.37&#x2A;</td>
<td>+5.62%</td>
<td>+13.70%</td>
</tr>
<tr>
<td>러셀 2000지수</td>
<td>2,114.35</td>
<td>+4.31%</td>
<td>+15.09%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">참고: &#x2A; 레코드 종가</figcaption></figure>
이번 분기 S&amp;P 500에서 가장 성과가 좋은 5개 중 3개는 반도체 부문에 속하는 기업들이다. 이는 AI가 이 부문에 주어진 동력을 과시하는 증거로 이어졌다. 이 목록의 선두를 <a target="_blank" href="https://www.benzinga.com/markets/equities/24/03/37440459/palantir-misses-out-super-micro-computer-makes-the-cut-what-investors-should-know-about-s-p-500-" rel="noopener">S&amp;P 500 데뷔자인</a> Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)가 차지했는데, 이 회사는 올해 들어 255% 이상의 수익을 창출했다. 다른 회사들은 다음과 같다: 
<ul>
<li>Nvidia (+83%)</li>
<li>Constellation Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NYSE">CEG</a>): +58%</li>
<li>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>): +41%</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>): +38%</li>
</ul>
한편, 부정적인 뉴스를 받은 기업들은 S&amp;P 500 종목 중 가장 나쁜 실적을 기록했다. 이 분기 동안에는 우리의 분기에 대한 보고서에서 여기서 29%와 26% 감소했다.
종합선물시장의 불황으로 인해 Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)와 Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)는 부정적인 헤드라인에 타격을 입었는데 소프트웨어 수요의 하락과 공급 측면의 병목 현상, 항공기 안전에 대한 우려 때문이었다..
 차터 커뮤니케이션 (바이커스: <a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), 거래 플랫폼 제공업체 MarketAxess Holdings Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) 및 의료 및 전문 보험 상품 제조업체 Humana, Inc.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)는 이번 분기 성능이 가장 나쁜 몇 가지 기업 중 하나로 선정되었다.
금의 눈부신 성과: 달러의 약세로 인해 금은 22년 만에 최고의 경기 침체를 기록했다. 또한 이에 따라 이는 현재 3월에 22년째로 최고의 경제지표를 나타냈다. 금은 미국 달러화에 역반비례하는 관계를 갖고 있기 때문에 이러한 경제지표에 의해 영향을 받게된다. 
1분기에는 금 선물이 종가를 기록한 2,254.80달러로, 이에 대한 기록적인 눈부시는 최고점으로 마무리 되었다. 
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td></td>
<td>Current Level</td>
<td>QTD Change</td>
<td>2023 Performance</td>
</tr>
<tr>
<td>Gold futures (Price/troy once)</td>
<td>2,254.80&#x2A;</td>
<td>+8.83%</td>
<td>+13.45%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">참고: &#x2A; 레코드 종가</figcaption></figure>
비트코인의 강세: 단순히 증권거래를 24시간 동안 할 수 있다는 이유로, 분기가 끝나기 전에는 세션을 더 진행할 수 있다. 
SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)의 투자 수익률을 통해 세 가지 자산 클래스의 투자 수익률을 비교하는 방식으로, 비트코인이 투자자들에게 가장 좋은 선택이 되었다는 것을 확인할 수 있다. 이번 연도 초에 투자한 1,000달러의 가치는 현재 1,673.84달러로, 이는 67.38%의 성과를 보여주고 있다. 
이번 년도 초에 각각의 1,000달러가 투자된 자산종목들은 현재 다음과 같은 가치를 보여주고 있다.
<figure class="wp-block-table">
<table>
<thead>
<tr>
<th>자산</th>
<th>초기 투자</th>
<th>현재 가치</th>
<th>수익률</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPY</td>
<td>1,000달러</td>
<td>1,103.90달러</td>
<td>10.39%</td>
</tr>
<tr>
<td>금</td>
<td>1,000달러</td>
<td>1,080.40달러</td>
<td>8.04%</td>
</tr>
<tr>
<td>비트코인</td>
<td>1,000달러</td>
<td>1,673.84달러</td>
<td>67.38%</td>
</tr>
</tbody>
</table>
</figure>
미래의 방향 금융 시장의 주요 추진 기구로 분석가들은 향후 이번년도 안으로 이러한 랠리가 지속될 것으로 예상하고 있다. 그러나 미국의 소비자물가지수(CPI), 개인소비지출지수(PCE), GDP 성장, 논피닐 근로자 수, 10년 만기 미국 국채 수익률과 같은 경제 지표들은 투자자들에게 중요한 역할을 할 것으로 예상된다. 
블루칩 데일리 트렌드 리포트(Blue Chip Daily Trend Report)의 주요 기술 전문가인 래리 텐타렐리(Larry Tentarelli)는 Benzinga와의 만남에서 이러한 주요 지표들이 시장의 결과에 미칠 영향에 대해 강조했다. 그는 또한 미국 연방준비제도(Fed)의 행동이 시장에 미칠 가장 큰 영향으로 보고했다. 
앨리언츠 투자 관리(Allianz Investment Management)의 시니어 투자 전략가인 찰리 립리(Charlie Ripley)는 텐타렐리와 동의했다. 그는 시장에 미칠 가장 큰 영향은 연방준비제도(Fed)의 행동이라고 강조했다. &#8220;연방준비제도의 현재 입장은 올해 내 3차례의 금리 인하를 추구한다는 것이지만, 인플레이션 지표들이 점차 안정되어 있는 것 같다면 그들의 선은 금방 바뀔 수 있다&#8221;고 그는 말했다. 리플리는 이후에 집중리스크를 대비했다. 이번 년도에 연방준비제도와 어떠한 인플레이션 지표들 사이의 상관관계가 있을지에 대해 주목할 것으로 예상하고 있다. 
텐

Comments

Humana

뉴스

에 대한 최신 뉴스 Humana (NYSE:HUM) 주식

수요일, 10월 02, 2024

일요일, 9월 15, 2024

화요일, 4월 02, 2024

금요일, 3월 29, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌